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Background: Vascular lesions involving the thoracic aorta are often life-threatening conditions that carry significant
morbidity and mortality with traditional open surgical repair. Preliminary results suggest that endovascular therapy is an
effective and possibly advantageous treatment for diseases of the descending thoracic aorta.
Methods: Between October 2000 andMay 2004, 50 consecutive patients underwent endovascular stent-grafting of lesions
involving the descending thoracic aorta. Attempted stent-graft deployment was performed electively in 39 patients and
emergently in 11. The pathology of electively treated aortic lesions included degenerative/atherosclerotic aneurysms
(n 24), pseudoaneurysms (n 11), aortic dissections (n 2), and penetrating ulcers (n 2). Emergently treated aortic
lesions were for acute rupture due to infectious (mycotic) aneurysms (n  4), atherosclerotic/degenerative aneurysms
(n  3), acute type B dissections (n  2), and acute transections (n  2). Devices used include Talent (n  45), AneuRx
aortic cuffs (n  2), custom-fabricated Gianturco-Dacron grafts (n  2), and a modified Cook-Zenith abdominal aortic
graft (n  1). Follow-up was performed at 1-month, 6-months, 1-year, and annually thereafter.
Results: Primary technical success, defined as successful deployment and exclusion of the lesion without evidence of type
I or type III endoleak, was achieved in 48 (96%) of 50 patients. In one patient, the procedure was terminated due to
inability to access the iliac vessels. In another patient, a type III endoleak was observed at the completion of the primary
procedure that required deployment of an additional stent-graft component 2 months later. Of the 49 patients who
received endografts, seven underwent secondary procedures to correct endoleaks, with five of these seven requiring the
deployment of additional endovascular stent-graft components. Major complications included four in-hospital deaths,
with three of these occurring in patients treated emergently. Additionally, respiratory failure (n 6), multisystem organ
failure (n 2), cerebrovascular accident (n 2), retroperitoneal hematoma (n 2), acute renal insufficiency (n 1), and
pulmonary embolus (n 1) were also observed. The overall endoleak rate was 20%, with five primary (<30 days) and five
secondary (>30 days) endoleaks observed. Five of the endoleaks were treated with the deployment of one or more
additional endovascular stent-graft components. Two of the endoleaks were treated with endovascular balloon remold-
ing. Mean follow-up was 271 days. There were no aneurysm ruptures or aneurysm-related deaths.
Conclusions: Endovascular treatment of vascular lesions involving the descending thoracic aorta can be safely performed
with low morbidity in high-risk patients. Endovascular repair may become an attractive alternative for the treatment of
a wide range of pathology along this vascular territory. (J Vasc Surg 2005;42:1063–74.)Without treatment, most aneurysmal lesions and dis-
sections involving the descending thoracic aorta will
rupture, with subsequent death of the patient.1,2 Al-
though medical management of some Stanford type B
dissections confers a survival advantage over open surgi-
cal intervention,3 there remains a substantial concern of
progression of the dissection, aneurysmal dilatation, and
subsequent rupture.4 Despite the risks of traditional
open repair, surgery greatly reduces the risk of rupture
and improves overall survival.1,5,6 Emergent open surgi-
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doi:10.1016/j.jvs.2005.08.001cal treatment for thoracic aortic rupture carries a very
high mortality.7-9 Because of the frequency of associated
comorbidities in this patient population or associated
injuries in patients with traumatic lesions, patients are
often assessed to be unsuitable candidates for open sur-
gical intervention. The advent and applicability of endo-
vascular stent-grafts to lesions involving the descending
thoracic aorta has the potential to decrease morbidity
and mortality as well as expand the number of patients to
whom intervention can safely be offered.
A recently published randomized study comparing
endovascular repair with traditional open surgical repair
for the treatment of infrarenal abdominal aortic aneu-
rysms (AAAs) demonstrated significant advantages in
mortality and morbidity with endovascular therapy.10
Early experience with use of stent-grafts to treat of
AAAs, and refinements in endovascular techniques, led
to the application of this technology to lesions involving
the descending thoracic aorta. Mid-term results with
handmade, first-generation devices have suggested ad-
vantages in mortality and morbidity.11,12 The purpose of
this study is to review our initial experience with the use
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lesions involving the descending thoracic aorta.
MATERIALS AND METHODS
A retrospective review of all patients who underwent
endovascular repair of thoracic aortic lesions between Oc-
tober 2000 and May 2004 was performed at our institu-
tion. The 50 patients described in this report represent the
first 50 consecutive attempted endovascular repairs of tho-
racic aortic lesions performed at the University of North
Carolina Hospitals.
All electively treated, and most of the emergently
treated patients, underwent preoperative imaging at our
institution. Preoperative evaluation consisted of computed
tomography (CT) angiography of the chest, abdomen, and
pelvis with multiplanar reconstruction. When medically
indicated, magnetic resonance angiography (MRA) was
substituted for CT evaluation.
Follow-up was routinely performed at 1 month,
6 months, 1 year, and annually thereafter. When patients
did not attend their scheduled follow-up appointment,
Table I. Characteristics of patients undergoing thoracic
stent-graft repair
%
n (n/50)
Patients 50
Male 30 60
Female 20 40
Age (years)
Mean 70
Range 26-89
Race
White 39 78
African-American 7 14
Othera 4 8
ASA classificationb
ASA I 0 0
ASA II 2 4
ASA III 35 70
ASA IV 13 26
Comorbidities
Hypertension 44 88
Current/prior tobacco use 40 80
Coronary artery disease 28 56
COPD 18 36
Peripheral vascular disease 13 26
Current/prior alcohol abuse 11 22
Diabetes mellitus 10 20
Prior open AAA repair 10 20
AAA present 9 18
CRI 9 18
End-stage renal disease 2 4
Operative category
Elective 39 88
Emergent 11 22
COPD, Chronic obstructive pulmonary disease; AAA, abdominal aortic
aneurysm; CRI, chronic renal insufficiency.
aAsian, Portuguese, Hispanic, and not classified.
bAmerican Society of Anesthesiologists (ASA) physical status classification.attempts were made to contact the patient’s family or carefacility to determine the patient’s current health status.
Follow-up included both cross-sectional and plain film
imaging.
Informed consent and institutional review board (IRB)
approval was obtained for the recording andmaintaining of
data for patients involved in investigation device exemption
trials. Additionally, IRB approval was granted for review of
all patient records relevant to this review.
Patient demographics and clinic and radiologic data
were obtained from electronic and paper records. Forty-
one of the patients (82%) in this study had three or more
comorbidities (Table I). Additionally, 48 of the patients
(96%) were assessed to have an American Society of Anes-
thesiologists (ASA) physical status classification of3. The
etiology of all 50 descending thoracic aortic lesions is
presented in Table II.
Of the 50 patients who received endografts, 11 were
deployed on an emergent basis. Emergently treated de-
scending thoracic lesions included 4 ruptured infectious
(mycotic) aneurysms, 3 ruptured degenerative/athero-
Table II. Descending thoracic aorta disease etiology in
patients undergoing thoracic stent-graft repair
%
Lesion n (n/50)
Elective endovascular repairs 39 78
Aneurysms/Pseudoaneurysms 35 70
Degenerative/Atherosclerotic 24 48
Fusiforma 20 40
Thoracoabdominal type IV 1
Saccular 4 8
Mean degenerative/atherosclerotic aneurysm
diameter (cm) 58
Pseudoaneurysms 11 22
Chronic transectionb 5 10
Anastomotic 3 6
Thoracoabdominal type IV 1
Post-traumaticc 2 4
Thoracoabdominal type IV 1
Chronic contained rupture 1 2
Mean pseudoaneurysm diameter (cm) 66
Dissections 2 4
Chronic dissection 2 4
Ehlers-Danlos syndrome 1 2
Penetrating ulcer 2 4
Emergent repairs (all acute ruptures) 11 22
Infectious (mycotic)d 4 8
Thoracoabdominal type IV 1
Degenerative/atherosclerotic 3 6
Traumatic (acute transection) 2 4
Acute Stanford type B dissection 2 4
aOne fusiform aneurysm had an associated pseudoaneurysm from a pene-
trating ulcer.
bHistory of blunt trauma. All five patients reported a remote history of blunt
chest trauma due to a motor vehicle collision.
cHistory of penetrating trauma. One patient reported a prior history of a
shotgun wound to the chest. The other patient reported a history of a
shotgun wound to the mid-upper abdomen.
dOne ruptured mycotic pseudoaneurysm presented with an aortobronchial
fistula.sclerotic aneurysms, 2 acute aortic transections from blunt
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ruptures of acute type B dissections.
The general criteria used to determine anatomic suit-
ability for endovascular repair of all thoracic aneurysms in
this series was a proximal and distal aortic neck of2 cm in
length for elective cases. The endografts were oversized
approximately 10% to 20%, but did not exceed 30%, in
relation to the maximal diameter of the proximal and distal
attachment sites and varied according to the type of aortic
pathology. Most of the devices were the Talent Thoracic
Stent-Graft System (Medtronic AVE, Santa Rosa, Calif)
(n  45, 90%). Emergently utilized Talent thoracic en-
dografts were usually obtained in 24 hours on an emer-
gent use/compassionate use basis from the manufacturer.
Other endoprosthesis utilized due to a lack of availabil-
ity of commercially made stent-grafts included handmade
endografts constructed from Gianturco Z-stents (Cook, Inc,
Bloomington, Ind) and woven Dacron (DuPont, Wilming-
ton, Del) polyester fabric graft as described previously,13
AneuRx aortic extender cuffs (Medtronic AVE) commonly
used for proximal extension of the bifurcated stent-graft of
the AneuRx AAA Stent Graft System, and a modified
Cook-Zenith AAA Endovascular Graft (Cook, Inc).
Cerebrospinal fluid (CSF) drainage was used routinely
for all patients believed to be at risk for spinal cord ischemia
due to previous open or endovascular AAA repair (n 10).
CSF drainage was also performed in one patient with a
thoracoabdominal aortic aneurysm who underwent aor-
tomesenteric bypass grafting at the time of endovascular
repair. No additional adjuncts to prevent spinal cord isch-
emia were used.
Endograft components manufactured for repair of
AAAs were utilized in three patients due to a lack of
commercially available thoracic endografts. In the first pa-
tient, exclusion of an anastomotic pseudoaneurysm occur-
ring in a thoracoabdominal type IV distribution was re-
paired with two AneuRx aortic cuffs. The techniques
utilized in this patient have been previously reported.14 The
second patient in which an AneuRx aortic cuff was de-
ployed was treated for a contained ruptured mycotic pseu-
doaneurysm located in the distal descending thoracic aorta.
A Cook-Zenith AAA Endovascular Graft was emergently
utilized in a patient with a ruptured mycotic pseudoaneu-
rysm who presented with an aortobronchial fistula.
Nine patients underwent additional vascular proce-
dures at the time of the initial operation (Table III). Six of
the nine procedures were for access vessel repairs and were
unplanned. Two of the access site repairs occurred in the
five cases of attempted iliac access. The rest occurred in
patients in which access was obtained through the femoral
artery. Two patients underwent planned iliorenal bypass
grafting, and one patient underwent a planned open aortic-
celiac artery bypass, as well as an aortic-superior mesenteric
bypass, in which polytetrafluoroethylene (PTFE) grafts
were used. The later patient presented with chronic mesen-
teric ischemia secondary to a chronic dissection involving
the visceral vessels and a saccular aneurysm involving most
of the descending thoracic aorta.Primary and short-term outcomes, as well as endoleak
classification, are defined as described previously.15 Survival
time was measured from the time of stent-graft deployment
until death or the patient’s most recent clinic follow-up.
Freedom from endoleak was measured from the time of
stent-graft deployment to the time of type I or type III
endoleak detection on CT or MRA evaluation, or time of
most recent follow-up for patients who remained endoleak-
free.
Analysis of survival and freedom from endoleak was
performed using the Kaplan-Meier method and log-rank
test. P  .05 was considered to be statistically significant.
The detection of an endoleak on radiologic evaluation was
considered an event defining clinical failure for freedom
Table III. Operative data in cohort undergoing thoracic
stent-graft repair
%
n (n/50)
Anesthesia
General 34 68
Epidural 14 28
Spinal 2 4
Additional vascular procedures 9 18
Access site repairs 6 12
Interposition/Bypass graft 3 6
Endovascular Stent/
Stent-Grafting 3 6
Iliorenal bypass 2 4
Aortomesenteric bypass 1 2
Operative time (min)
Mean 156
Range 69-697
Estimated blood loss (mL)
Mean 223
Range 20-3000
Access site
Femoral artery 43 86
Iliac artery 5 10
Abdominal aorta 2 4
Endografts deployed 49/50 98
Endografts successfully deployeda 48/50 96
Left subclavian artery covered 5 10
Partial left subclavian artery coverage 4 8
(n/49)
Types of endografts deployed 49
Talent 44 89.8
AneuRx aortic cuffs 2 4.1
Customb 2 4.1
Cook-Zenith TFB-032-132 1 2.0
Patients receiving a single
component 14 28.6
Patients receiving multiple
components 35 71.4
Mean number of components
deployed 2.2
aEndografts deployed and free of type I, II, or III endoleaks at the conclu-
sion of the procedure.
bConstructed from Gianturco Z-stents and woven Dacron graft.from endoleak analysis.
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A summary of primary and short-term outcomes is in
Table V. Primary technical success, defined as successful
deployment of the endograft with exclusion of the aneu-
rysm or pseudoaneurysm thereby demonstrating the ab-
sence of either a type I or type III endoleak, or coverage of
the proximal entry tear in aortic dissection, was obtained
in 48 patients (96%). In one patient, a type III endoleak
was observed after deployment of four Talent endograft
components for the treatment of an anastomotic pseu-
doaneurysm. Because an appropriately configured en-
dograft component was not available, the procedure was
concluded, and the patient chose to have a secondary
endovascular procedure 2months later. The patient’s pseu-
doaneurysm remains excluded, with no evidence of en-
doleak, 30 months after his secondary procedure.
In another patient, the Talent endograft could not be
advanced through the iliac artery, and the patient sustained
a dissection of the vessel requiring termination of the
procedure and repair of the vascular injury with endovas-
cular stents. At follow-up, the patient elected to not un-
dergo second procedure that would have required vascular
access through a previously repaired AAA.
There were no aneurysm-related deaths, defined as
deaths directly attributed to aneurysm rupture, the primary
procedure, or subsequent secondary procedures. The
30-day all cause mortality was 8% (n  4). For elective
procedures, the 30-day mortality was 2.6% (n 1), and the
late mortality (30 days) was 5.1% (n  2). For emergent
procedures, the 30-day mortality was 27.3% (n  3), and
the late mortality was 27.3% (n  3). Causes of death
within the first 30 days included respiratory arrest in a
patient who requested “do not resuscitate/do not intu-
bate” status, withdrawal of care in a patient who sustained
multiple injuries secondary to a motor vehicle crash, and in
the other two, multisystem organ failure (MSOF), defined
as the irreversible failure of two or more organ systems.
Affected organ systems for the patients who experienced
MSOFwere not subclassified in the final analysis of complica-
tions. One of the patients who died from MSOF had been
treated electively and involved a hybrid open-endovascular
procedure to correct severe mesenteric ischemia.
Late deaths occurred in five patients and were attrib-
uted to complications of end-stage renal disease, complica-
tions of cirrhosis, and congestive heart failure while in the
care of a hospice program, complications of severe periph-
eral vascular disease, withdrawal of care in a patient with
respiratory failure who sustained lower-extremity paralysis
preprocedurally as a complication of a ruptured aneurysm,
and of undetermined cause.
Kaplan-Meier analysis revealed a combined overall sur-
vival estimate for elective and emergent repairs at 1 and
3 years of 79.4% and 79.4% (Fig 1). For electively treated
patients, 1- and 3-year survival estimates were both 91.4%.
The 1-year survival estimate for emergently treated patients
was 37.4%. The survival difference between patients under-going elective and emergent procedures was significant
(P  .05).
Mean intensive care unit (ICU) stay was 6.8 days for
the 19 patients (38%) who required ICU care after comple-
tion of their procedure. The 11 patients treated emergently
were all admitted to the ICU postprocedurally and stayed a
mean of 7.7 days (range, 1.3 to 29.3 days).
Two patients experienced MSOF, as described. Post-
operative myocardial infarction and acute renal failure did
not occur independently of MSOF; however, respiratory
failure occurred independently ofMSOF in six patients, five
of whom had been treated emergently. Five patients had to
be reintubated at some point during their postoperative
course, and all had undergone a general anesthetic. Two
patients experienced cerebrovascular accidents. One of the
patients had undergone endovascular balloon molding of
the proximal portion of the stent-graft and the other had
atherosclerotic aortic arch disease, which may have been a
source of emboli. The most frequently observed complica-
tions were of the urinary tract (24%), with urinary retention
after Foley catheter removal occurring in 18%, and laboratory-
documented urinary tact infections occurred in 10% of
patients.
Nine patients had near or total occlusion of the origin
of the left subclavian artery (LSA). Two of the five patients
who had complete coverage reported symptoms of left
upper-extremity claudication at follow-up. The severity of
the patients’ symptoms did not dictate an additional inter-
vention to address their symptoms. None of the patients in
this study underwent prophylactic left subclavian-carotid
artery transposition or left carotid-subclavian artery bypass.
The femoral artery was accessed in 43 patients (86%).
Access through the iliac artery was attempted in five cases;
Fig 1. Kaplan-Meier life table survival analysis of patients after
elective or emergent endovascular repair of thoracic aortic lesions.
Standard error for the elective group did not exceed 10%. Broken
line represents 10% standard error.in two of which, access to the arterial system was facilitated
Type IB 3 6
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upon preoperative imaging studies and intraoperative eval-
uation. Access site complications included two patients
with retroperitoneal hematomas who were managed con-
servatively and four patients with access site hematomas, of
which two required a limited surgical intervention to evac-
uate the hematoma during their hospital stay.
Repair of access vessels due to trauma sustained from
the deployment device (n  6) were all performed at the
time of the initial procedure, and included the placement of
an ileofemoral bypass graft in 1, interposition bypass graft
in 2, deployment of a stent-graft in 1, and deployment of
endovascular stents in 2. No patients developed symptoms
of lower-extremity ischemia due to complications involving
access vessels. Additionally, no patients displayed postpro-
cedural signs or symptoms of distal embolic occlusion.
Endoleaks were defined and classified as previously
described.15 Five primary (30 days) and five secondary
(30 days) endoleaks were observed. The types of en-
doleak are listed in Table IV. All endoleaks occurred in
patients who had received a Talent endograft (P  NS).
Four of the five primary endoleaks were treated with a
secondary endovascular procedure. Two patients were
treated for type III endoleaks with the deployment of
additional endovascular components (1 component each),
and the other two patients (type IA and type IB endoleaks)
were treated with endovascular balloon remolding. The
patient who did not undergo a secondary procedure had a
type IB endoleak and died 36 days after his procedure from
complications of pre-existing end-stage renal disease.
Three of the patients with secondary endoleaks (type
IB, type IB, type III endoleaks) underwent secondary
endovascular procedures. These patients received 1, 2, and
3 additional endovascular components, respectively. The
two patients with secondary endoleaks who did not receive
an intervention had a type IB and a type II endoleak. The
patient with the type IB endoleak died 4.5 months after his
stent-graft deployment following withdrawal of supportive
care. This patient had pre-existing upper- and lower-
extremity paralysis as a complication of a ruptured athero-
Table IV. Continued.
%
n (n/50)
Type II 1 2
Type III 1 2
ICU, Intensive care unit.
aBlood transfusion given intraoperatively through 24 hours postoperatively.
bCardiac, pulmonary, and renal complication in these two patients not
subdivided among the respective categories.
cBoth patients who developed pneumonia were reintubated for respiratory
failure.
dTwo patients who experienced urinary retention were also treated for
urinary tract infections.
eBoth patients had their left subclavian artery covered by the proximal
portion of the endograft.Table IV. Complications occurring in patients
undergoing thoracic stent-graft repair
%
n (n/50)
Length of hospital stay
Mean (days) 7.2
Range (days) 1-64
Discharged home by hospital day 3 29 58
ICU stay
Patients requiring admission to ICU 19 38
Mean (n  19) (days) 6.8
Range (n  19) (days) 0.2-29.3
Complications
Blood transfusionsa 18 36
Total units of packed red cells 49
Mean units of transfused packed cells/
patient 1.0
Blood transfusions (24 hrs-30 days
postprocedure) 12 24
Total units of packed red cells 39
Mean units of transfused packed cells/
patient 0.8
Multisystem organ failureb 2 4
Cardiac 3 6
Myocardial infarction 0 0
New onset arrhythmia 3 6
Respiratoryc 7 14
Respiratory failure 6 12
Reintubation 5 10
Pneumonia 2 4
Pulmonary embolus 1 2
Renal 1 2
Acute renal insufficiency 1 2
Acute renal failure 0 0
Gastrointestinal 2 4
Ileus 2 4
Urinaryd 12 24
Urinary retention 9 18
Urinary tract infection 5 10
Neurologic 2 4
Cerebrovascular accident 2 4
Lower-extremity paralysis 0 0
Lower-extremity paraparesis 0 0
Left upper-extremity ischemia 0 0
Left upper-extremity claudicatione 2 4
Retroperitoneal hematoma 2 4
Access site hematoma 4 8
Access site vascular repairs 6 12
Secondary endovascular procedures 7
Additional endovascular component(s)
deployment 5
Mean number of additional
components deployed 1.6
Range 1-3
Balloon plasty of stent-graft 2
Mean days postprimary procedure 213
Endoleaks
Primary endoleaks (30 days) 5 10
Type IA 1 2
Type IB 2 4
Type II 0 0
Type III 2 4
Secondary endoleaks (30 days) 5 10
Type IA 0 0sclerotic aneurysm before stent-graft placement.
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diagnosed by a CT scan at the 12-month follow-up, and the
leak was found to be originating from a small intercostal
branch within the excluded aneurysm. A repeat CT scan
performed 6 months later demonstrated no significant
change in the dimension of the aneurysm sac. No interven-
tion was recommended, and the patient will be re-evaluated
with a repeat CT scan in 6months. For subsequent analysis,
the patient was defined as having obtained technical and
clinical success as per previously proposed classifications.15
Although follow-up is limited, in the patients who re-
mained free of endoleaks, follow-up CT scans showed no
evidence of aneurysm sac enlargement. Additionally, no pa-
tients displayed evidence of stent-graft fracture or device
fatigue on follow-up four-view chest radiography.
Kaplan-Meier analysis revealed an overall combined
freedom from endoleak estimate of 78.8% at 1 year and
78.8% at 2 years based upon radiologic imaging or
endoleak-free follow-up (Fig 2). Elective repairs had a
1-year and 2-year endoleak-free survival estimate of
80.6% and 80.6%. The standard error for the Kaplan-
Meier freedom-from-endoleak curve estimate was 10%
beyond 27 months for both the overall and elective
groups. Additionally, the standard error was 10% after
1 month for Kaplan-Meier analysis of the emergent
group. Endoleak-free survival differences between elec-
tive and emergent repairs were not significant (P  .05).
DISCUSSION
In 1991, Parodi et al16 was the first to describe the use
Table V. Summary of primary and short-term outcomes
in patients undergoing thoracic stent-graft repair
n %
Follow-up (days)a
Mean (n  49) 271
Range 1-1101
(n/50)
Primary technical successb 48 96
Initial (30-day) clinical success 44 88
Assisted initial clinical success 46 92
Short-term (30 days) clinical successc 40 80
Assisted short-term clinical success 47 94
(n/49)
Estimated freedom from type I and III
endoleak at 1 yeard 78.8
(n/50)
All cause 30-day mortality 4 8
Procedure-related deaths 0 0
Aneurysm-related deaths 0 0
Late deaths (30 days) 5 10
Aneurysm-related deaths 0 0
Post-procedure aneurysm rupture 0 0
aMost recent evaluation at clinic follow-up or post-procedure day of death.
bOne failure to access the arterial system and one type III endoleak seen at
completion.
cNot including one type II endoleak observed in one patient.
dBased upon Kaplan-Meier analysis at a mean of 7.3 months.of stent-graft technology to treat AAAs utilizing a hand-made balloon-expandable Dacron-graft-covered Palmaz-
type stents.16 In 1992, the Stanford group began using
self-expanding stainless steel Z-stents covered with woven
Dacron graft to treat lesions in the descending thoracic
aorta, and reported their initial experience in 1994.13 Mid-
term results from the utilization of these handmade first-
generation stent-grafts have been encouraging and suggest
the feasibility of this technology to treat a wide variety of
descending thoracic aortic lesions.12
Despite the advances made in the treatment of infrare-
nal AAAs, the application of endovascular technology and
commercial development of stent-grafts to treat lesions
occurring along the descending thoracic aorta has lagged
behind by comparison. This can be attributed to the smaller
perceived incidence of thoracic aortic lesions, the frequent
involvement of arch vessels precluding stent-graft utiliza-
tion, and other vascular anatomic characteristics that may
prohibit endovascular repair.
Despite these limitations, the incidence of thoracic
aortic aneurysms and other thoracic aortic lesions can be
anticipated to increase. This projected proliferation can be
attributed to our aging population and the increased use of
diagnostic procedures for other thoracic pathology, such as
the evaluation of trauma patients who sustain blunt chest
wall trauma.17 Along with the aging of the population
comes an increased association of medical comorbidities
that may preclude an open surgical intervention. An endo-
vascular approach affords a potentially less invasive proce-
dure with resultant decreased morbidity and mortality.
Current reports of single institutional experiences with
commercially manufactured endoprostheses have been lim-
ited by a lack of long-term data, institutional learning
curves, a limited volume encompassing a wide range of
thoracic aortic pathology, variability in patient population,
and a variety of stent-graft designs. Despite these limita-
tions, the initial results from these studies suggest improve-
ments in graft delivery, deployment, and fixation, demon-
strating advancements over first-generation devices.18-26
An endovascular approach to the repair of thoracic
aortic lesions is believed to confer advantages in perioper-
ative mortality over traditional open repair. In-hospital and
30-daymortality for combined emergent and nonemergent
case series treated by standard surgical repair have been
reported to range from 5.5% to 22.6%.5,7,8,27-29 Nonemer-
gent open repair carries a perioperative mortality of 6.5%
to 19%.5,7,8,28,30 These results are slightly higher then
the 9% 30-day mortality reported for first-generation
stent-grafts.12,31
Additionally, the EUROSTAR collaborators recently
reported on 443 patients who underwent endovascular
repair of thoracic aortic disease utilizing commercially avail-
able stent-grafts with a 30-day mortality of 9.3%.32 These
findings are slightly higher then the hospital deaths,
perioperative deaths, and/or 30-day mortalities (0% to
6%) reported by other large institutional series (40
patients) in which commercially available stent-grafts were
used.18,20,21,23,26 Our observed all-cause 30-day mortality
rate of 8% is consistent with these findings. Comparisons
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repair are difficult given that many of the patients who
undergo endovascular repair are not deemed operative
candidates because of their associated comorbidities.
Postprocedure paraplegia/paraparesis is a serious com-
plication of both open and endovascular repair of thoracic
aortic lesions. Open repair of descending thoracic aneu-
rysms has been reported to carry a postoperative paraplegia/
paraparesis rate of 2% to 6.2%.5,8,27,29,30 The paraplegia/
paraparesis rates for handmade first-generation devices
were reported to be 0% to 3%.11,12 More recent studies
involving commercially available endografts report simi-
lar findings of permanent paraplegia/paraparesis rates of
0% to 4%.18,20,21,23,26,32
In our series, there were no cases of postprocedure
paralysis consistent with these previous reports. Paralysis
observed in open repair is associated with the length of the
interposition graft, duration of the operative procedure,
and duration of aortic cross-clamping, all aspects of which
are either minimized or absent with an endovascular ap-
proach. Paralysis from endovascular repair may result from
the coverage of critical intercostals arteries. Of the 49
Fig 2. Kaplan-Meier life table endoleak analysis show
undergoing elective or emergent endovascular repair of
error.patients in our series who received stent-grafts, 10 hadundergone a previous open AAA repair and 9 had an AAA
present.
CSF drainage was routinely used in patients believed to
be at risk for spinal cord ischemia due prior interruption of
lumbar collateral flow during a previous open or endovas-
cular AAA repair. The possible increased risk of postproce-
dure paraplegia in patients who have undergone prior open
or endovascular AAA repair, or have thrombosed lumbar
arteries from a concurrent AAA, remains to be defined in
patients who receive a thoracic endograft but maybe related
to reduced spinal cord blood flow below a critical level.
Although CSF drainage has been reported to be a useful
adjunct in the prevention of spinal cord ischemia in patients
undergoing open surgical repair,33 the utility of this pre-
ventative intervention in endovascularly treated patients
who are not subjected to a longer procedure, nor hypoper-
fusion of the spinal artery, remains to be demonstrated.
Concern about the development of left upper-extremity
ischemia and vertebral artery steal as a result of coverage of
the LSA after graft deployment led to the practice of
prophylactic left subclavian-carotid artery transposition, or
left carotid-subclavian artery bypass in patients where LSA
edom from type I or type III endoleak in patients
cic aortic lesions. Broken line represents 10% standards fre
thoracoverage would be required to obtain an adequate proximal
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tions of a dominant left vertebral artery, an aberrant right
vertebral artery, or prior left internal thoracic-coronary
artery bypass, coverage of the ostium of the LSA is now
expectantly managed, as intentional coverage appears to be
well tolerated given the potential collateral blood supply
around the LSA.11,34
We routinely perform MRA on all patients in which
LSA coverage will be necessary to obtain a proximal seal to
identify those patients with a vascular anatomy at risk from
LSA compromise. Of the five patients in our series who had
complete coverage of their LSA by the proximal portion of
the stent-graft, two experienced symptoms of left upper-
extremity claudication that did not required surgical revas-
cularization, further supporting the expectant management
of LSA occlusion.
When endoleaks are detected after thoracoabdominal
aortic aneurysm repair, they are more likely to occur as type
I endoleaks due to incomplete sealing at the attachment
sites.32,35 First-generation endografts had a reported pri-
mary endoleak rate of approximately 20% and a secondary
endoleak rate of 21% at mid-term follow-up.12 This high
rate of endoleak can be attributed to the relative inflexibility
of first-generation devices. Commercially manufactured
second-generation devices have been designed to address
this complication.31,35 Primary endoleak rates with com-
mercially produced second-generation devices have been
reported at 3% to 11%.18,20,23,32 Secondary endoleak rates
with these devices have been reported at 7% to 28.9%,
although the length of reported follow-up is variable.20,23
The actual risk of experiencing a secondary endoleak
over the lifetime of the endograft will become defined with
the availability of long-term results and will most likely vary
by etiology of the thoracic lesion and possibly by the type of
commercial stent-graft employed. Our primary endoleak
rate of 10% is consistent with these previous studies. Our
secondary endoleak rate of 10% is probably an underesti-
mation of the long-term risk of endoleak occurrence, given
that most of our patients have only followed-up in the
short-term.
Emergent repairs of the thoracic aortic lesions are often
performed for contained rupture of aortic aneurysms, trau-
matic transections, and acute dissections. Emergent open-
repair of these lesions carries a high 30-day or in-hospital
mortality rate of 18.6% to 31.4%, as well as a high
paraplegia/paraparesis rate of 5.5% to 27%.3,5,7-9 The mor-
bidity imposed upon patients with coexisting injuries from
the techniques performed during an open repair can also be
substantial. By comparison, emergent endovascular repair
of thoracic lesions has a reported 30-day or in-hospital
mortality rate 0% to 33% and a paraplegia rate of
0%.19,22,25,36 Although our 30-day mortality and late mor-
tality rate for emergent procedures was 27.3% and 27.3%,
respectively, there were no aneurysm-related deaths, and
five of the six patients were known to have died from
complications of injuries or pre-existing comorbidities.
The applicability of endovascular stent-grafts to lesions
in the thoracic aorta is mainly limited by vascular anatomy.The larger devices and delivery systems needed to reach and
exclude thoracic lesions, compared with lesions involving
the abdominal aorta, often preclude endovascular repair in
patients with small or tortuous access vessels. Additionally,
severe angulation of the descending aorta may impair nav-
igation and deployment of the stent-graft. Arch vessel
involvement often disallows an adequate proximal landing
zone, just as visceral and renal vessel involvement create
problems for the distal landing zone in more extensive
thoracoabdominal lesions.
Improvements in commercially available stent-grafts,
investigator experience, and the development of new tech-
niques have addressed some of these initial limitations.
Current devices are smaller, more flexible, and impose less
resistance to arterial blood flow than handmade first-
generation devices, allowing improved navigation and a
greater accuracy in deployment.31,35 Additionally, tech-
niques to address landing zone limitations imposed by the
arch vessel origins have been described.24,37 Long-term
data on these commercially manufactured endografts and
adjunct techniques are needed to define graft durability,
the need for secondary intervention, and freedom from
aneurysm-related death.
CONCLUSION
As with previously reported single institution studies,
the results of our review are limited by our present short-
term follow-up and wide variety of thoracic aortic pathol-
ogy precluding long-term durability conclusions. Our
results suggest that thoracic endografts can be safely de-
ployed in high-risk individuals with a low morbidity.
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DrAlan Lumsden (Houston, Tex). Mark, thank you for the
opportunity to review the manuscript. As you know, as a
discussant, we are often lucky to get the manuscript within 24
hours of the presentation; in your case, you gave me the
manuscript so long ago that I forgot that I had it. Congratula-
tions then on being sufficiently organized to write the manu-
script and for a beautiful presentation. And I want to congrat-
ulate you on one other level, and that is in generating one of the
largest thoracic experiences in the vascular surgery community.
As a vascular surgeon, I am tired of playing defense on my turf
and commend you on extending ______ what is often regarded
as somebody else’s turf, and then I’ll come back to some
questions. I think there are many lessons that you can teach us
from that standpoint. As the membership may or may not know,
the Gore Excluder was approved by the FDA’s scientific panel
last week. The implication of that is that we will potentially have
a commercially available endograft in our hands probably in thetraining hysteria will move on from carotid stenting and next
year we’ll be talking about training people in thoracic aortic
endograft.
Your study includes predominantly the Talent system since
you are part of the VALOR trial, and yet 11 patients were treated
on an emergent basis and you have included also homemade
devices that you have created and also cuffs from the infrarenal
approach. My question is whether any difference is really in the
outcomes that you noticed between the off-label use and those
which are really being manufactured specifically for the thoracic
aorta, in this case by Medtronic.
Some 10% of your patients required coverage of their left
subclavian artery. As you know, occasionally the contralateral
vertebral artery is occluded, and if we cover the left subclavian,
then that is something that is potentially catastrophic. At the
_____ meeting it was suggested that we always look at the
vertebral arteries in patients prior to covering the left subclavian
artery to make sure that there is antegrade flow in the contralat-
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and is it something that you advocate?
Finally, we have had a case of paralysis in the VALOR trial,
albeit temporary, and it occurred in a patient who really had no
other risk factors and had not had prior infrarenal aneurysm repair.
Why then, basically, not prophylax all the patients with spinal
drainage?
So in summary then, my questions and congratulations ______
on this manuscript but my questions are, number one, how did you
create the referral pattern that kind of allowed you to claim the
thoracic aorta in North Carolina as your turf? And number two,
what specific additional training requirements will the member-
ships here, who have a lot of experience now in infrarenal aortic
aneurysms, are they going to require in order to be, by this time
next year, starting to do routine thoracic aortic endografting?
Number three, do you do routine vertebral imaging if you are
planning to cover the left subclavian artery? And finally, why not
prophylax all patients with spinal drainage since it is truly a cata-
strophic complication, albeit a rare one, in patients who don’t have
risk factors?
Thank you very much for the opportunity to read your manu-
script and discuss this.
Dr. Mark A. Farber. Thank you, Alan. I must admit that the
manuscript was mainly written by Dr Paul Riesenman. He is one of
our second-year residents so he should be commended for getting
you that manuscript on time.
In terms of your questions, one that came up during your
discussion was the use of homemade devices, and were the out-
comes any different from that. I think that one take-home message
is what we had available to us over this 3½-year period. Early on,
obviously, Zenith aortic endografts were not available and so what
we used were short cuffs. In patients that have a small defect in the
aorta, such as a small, ruptured plaque, those will work okay, but
any significant pseudoaneurysmwhere we have to put in more than
one cuff is a potential problem. Those cuffs tend to push out into
the pseudoaneurysm and separate and it’s a problem. In those
patients, we therefore have gone to modification of the aortic graft
by Cook and we take a 132-cm-long Cook device, modify the
proximal and distal end, and give ourselves a tube graft and deploy
it. This, in essence, gives us a 10-cm-long graft. Now that problem
will be solved, as you have mentioned, since now we have condi-
tional approval for Gore and in the next quarter we will have a
device used for emergent cases.
In terms of the vertebral evaluation, those patients treated
electively actually get a carotid duplex and we can pick up any issues
with that and, if needed, an MRA or CTA to include the Circle of
Willis. If there is any question about the status of the vertebral
artery, we will actually do an angiogram prior to our procedure.
That methodology fails a little bit with the emergent cases. You can
evaluate that somewhat on the CT scans in these emergent pa-
tients, but sometimes you have to be careful and that maymake the
difference as to whether you partially cover the subclavian or
whether completely cover the subclavian. I think that if you look at
some of our patients, those that have 80% coverage don’t have any
symptoms and it is in those that have complete coverage of the
subclavian that you really have to be more careful. Obviously, as
everyone knows, LIMA grafts in patients that are dependent upon
the left subclavian need to be done ahead of the procedure, but we
have not run into that issue yet in our experience.
We have done an additional 20 patients since this report and
we still have not had any patients who needed their subclavian
revascularization. We have had one patient, however, that did
develop significant left arm ischemia in that additional 20 and what
we did was to just slide a stent in next to the thoracic stent graft and
revascularize her in that way. So there are other options that you
can do in an emergent fashion. She didn’t need the coverage from
a sealing standpoint. She just needed to be redone with a stent next
to the stent graft.
The two other aspects you asked about were spinal cord
drainage, not to do it in everyone. I think that it is interesting thateven patients with concomitant aneurysms who have significant
thrombus do not develop spinal cord ischemia. I don’t have an
answer. Spinal cord drainage catheters are not benign procedures.
If you look at our open thoracoabdominal experience, we have had
two patients that have had an epidural hematoma after placement
of one. Now, granted those patients are significantly more coagu-
lopathic after the procedures than these and maybe that led to it,
but this complication leads to a surgical decompression of the
spinal cord and that is a potential problem. The risk of an epidural
hematoma is about 0.1% to 0.3% in the literature, so you need to
weigh that with what we are seeing with endovascular thoracic
aneurysm repairs. It may not be unreasonable, if you have any
question, to put a drain in these patients.
In terms of the last two questions about referral patterns, I
have to admit that our referral pattern was made quite easy by the
president-elect of this society, Dr Keagy. He is, as you know, both
cardiac and vascular trained, and for years in our vascular
training fellowship, we did the thoracoabdominal aneurysms
and so the referrals were naturally already being sent to us, and
with our endovascular skills it, was easy for us to continue. I
think it is important that you be able to handle the open
complications, and from a standpoint of a turf issue, this is going
to be very hard because most vascular surgeons don’t practice with
privileges in the thoracic cavity and have not had previous experi-
ence treating thoracic aneurysms. Granted, most of these proce-
dures go well if you are an experienced endografter. You can run
into complications. Endovascular thoracic aneurysm repairs are
more difficult because you are dealing with longer catheters and
you have to keep that inmind. It would bemy suggestion that early
on, one team up with a cardiac surgeon, because they may have the
capture patients and the referral patterns already set in your hospi-
tal, and you have to be very cognizant of that.
In terms of next year and training, we would be happy to help.
The biggest problem with training for thoracic cases is you can’t
plan them as well as you can infrarenal. The incidence of disease is
significantly reduced compared with simple abdominal aneurysms,
and so we have actually archived all of our cases on videos. That will
help with training for individuals, but you do need to get addi-
tional experience with the devices and catheters. Onemust remem-
ber that half the cases, which are not reflected in ours series, are
from dissections. Those are the most complicated cases, and you
need the most experienced hands to deal with all the issues of
dissections. This is a whole different aspect of treating it. If you are
just going to use grafts for aneurysms, you are going to miss out
treating half the patients.
In terms of training requirements, as for carotids, this is going
to be a local issue. Thank you.
Dr G. Melville Williams (Baltimore, Md). I stand to say that
surgery for the simple descending thoracic aortic aneurysm is
doomed and stent-graft repair is obviously the way to go. There is
absolutely no question that the difference in morbidity between
the simple stent-graft repair of a small, short aneurysm in the
descending thoracic aorta clearly outweighs the morbidity that we
see with the thoracotomy and all the things we need to do to make
the operation safe for the patient.
However, I think the challenge in the thoracic aorta is related
to the arch and how close you go to the arch, and here, I think, is
where we need to sort of take stock of what cases we should do and
what the learning curve is. I don’t think anybody ought to learn
how to treat aortic dissection first before dealing with the descend-
ing thoracic aorta and the simple procedure. I think we are begin-
ning to recognize that as we get closer to the arch, we may be
substituting strokes for paraplegia, and this is something that I
think we need to pay a great deal of attention to as well as the
long-term outcome of putting these rather straight stent grafts into
curved structures like the arch.
Finally, my comment on paraplegia is dependent totally on the
amount of thoracic aorta that is covered. There is no risk of
paraplegia if you cover 5 inches of the thoracic aorta. However,
when you begin to cover the entire thoracic aorta, that would be
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Thanks.
Dr. Farber. Thanks, Mel, for those comments. I’m first going
to start with the arch issues. The arch issues are being addressed.
Most of the reports you see are for first-generation thoracic stent
grafts, and most of the devices when they first came out had a
connecting bar that made them fairly stiff. The companies have
modified that and all the companies are removing their connecting
bars and the columnar strength out of the devices to make them
more flexible to handle the issues of arch changes in the confirma-
tion. In addition to that, they are also providing us with a longer
stent-graft because it eats up a lot more length as they become
more flexible in that area and the companies are doing that. They
are also changing the way the proximal deployment mechanism is
occurring to make it a little safer in terms of stroke risk.
I think that you have to be very careful about doing your
proximal molding. You realize that if you do proximal molding of
the left subclavian and you blow the balloon up, and let’s say you
push a little debris out while your balloon is inflated, then the only
place the debris is going to go is up the carotids. We really try to
avoid that unless, for some reason, it is not about putting another
piece in further up that you really need to mold that and you have
to be very careful in terms of stroke risks. Those are the two biggest
issues—stroke risk and access complications—and devices will ac-
tually get smaller. Most of these are 23 or 25 French, in that range
size.
In terms of dissections, well, since the IFU for the devices
don’t carry a dissection, no one should be doing dissections early
on because they are all going to be under the constraints of IFU
guidelines and I’m sure the FDA is going to watch that, so I agree
with you in terms of that aspect.
The last comment was about the extensive thoracic aortic
coverage. I think that our approach is that if we cover an extensive
thoracic aorta and they have a previous or concomitant AAA repair,
that we would suggest a spinal cord drainage catheter. We have had
coverage including the left subclavian, all the way down to the
celiac artery, and not experienced spinal cord ischemia. I think it is
plausible to watch that patient very closely and put a spinal cord
drainage catheter in if they do develop it and there are reports of
that paraplegia resolving.
I think the other issue that you have to consider is your iliac
access. We have one patient who recently, about one month ago,
had a Cook device put in and we did not cover the left subclavian.
We covered a small 5-cm section of thoracic aorta. Every time this
guy stands up he complains his back hurts and his legs go kind of
numb and kind of wobbly and it goes away after 15 or 20 seconds.
Now the diagnosis that comes up is he has spinal cord steal
syndrome. Now he has good hypogastrics. He has a good subcla-
vian. It’s rare that that should happen, but there are now a couple
isolated reports that when you have poor hypogastric flow and
you’ve covered the left subclavian, even if you cover the wrong
section of the thoracic aorta, you may have some spinal cord steal.
Whether that is a subcomponent and may lead to paraplegia, right
now at 6 weeks, he hasn’t developed that and we’ll continue to
watch him, but I do caution even the small sections can cover it if
it is the main dominant artery.
Dr W. Anthony Lee (Gainesville, Fla). Mark, excellent pre-
sentation. I just want to let Alan know that our center is another
center that has made good progress down at UF with thoracic
endograft repair. Although our experience doesn’t exceed yours,
Mark, we approached close to about 50 in the last 4 years. I have
two questions for you.
In our subset of patients, and most of our experience has been
involved with industry-made grafts vs homemade grafts, we have
noted approximately a 30% incidence of what I can best term as
something like intercostals neuralgia, a kind of bizarre chest wall
pain that is not anginal-type at all but is highly refractory and has
not been terribly amenable to NSAIDs or anything like that. We
have tried Neurontin or similar type of agents without muchresolution. It has been very frustrating and people are significantly
affected by it.
The second thing is, you have noted that there was 0%
paraplegia rate. What has been your paraparesis rate, meaning just
subtle-to-significant weakness of the legs, not frank paralysis, such
that they have difficulty standing in the immediate perioperative
period, and how have you treated that in terms of elective postop-
erative spinal drainage or other adjunctive methods?
Dr Farber. Thanks, Anthony. In terms of this neuralgia, I also
have two patients that complained, and usually it is within the first
month to two months after insertion that they notice left-sided
pain. Now whether that is related to the device you use or the
percent over-sizing, I don’t think so. It may be stretching of that
and it’s hard for me to say. It does go away with time. and that’s the
hard part. You have to tell your patients that it will get better from
that standpoint. So we have also seen that, and it is a perplexing
problem because what it leads to is all of a sudden you get an extra
CT scan because you don’t know if you have an endoleak and so
forth and so you end up getting extra workup.
In terms of the lower-extremity problems, we actually have
had two patients with issues similar to yours. Both of those
patients immediately got a workup and it was immediately
postop. They said, “my legs just don’t feel normal.” It has not
been that they cannot walk; it has not been that they cannot
stand. They say, “my legs just feel funny.” You end up getting
an MRA, a neurology consult, and in one patient, he had
lumbosacral disease and he was on the table and it was the problem
with him lying in the bed. In the other patient, no diagnosis was
ever brought. He never had any definitive neurologic deficit, and
the MRA did not show any perfusion problems with the spinal
cord. He got better with time. There are some low-grade patients
that, you know, are in that area. The biggest thing is that if you
have any concern, put a spinal cord drainage catheter in because
waiting is only going to cause you problems if that is the case. As
long as it is not a risk to the patient in terms of that, then we
would put a spinal cord drainage catheter in.
Dr Christopher Kwolek (Boston, Mass). I’d like to first echo
Dr. Williams’ comments. I think as a center where we do a lot of
open thoracoabdominal aneurysm repair, our group is convinced
that this is a lifesaving adjunct in many of our patients, both for
elective and, as Mark pointed out, for the emergent cases. I think
there are a couple important teaching points, training points, that
Mark sort of brought out that may have been missed in the paper.
One of them is when you look at your reintervention rate with
secondary endografts, I wonder if you would comment a little
bit about degree of overlap and length of devices, because we
found in our earlier experience when we were going with
less-than-significant overlap, we found ourselves reintervening on
a not insignificant number of patients because of changes in the
confirmation of the aneurysm sac separation. Now, we will rou-
tinely overlap up to 50%, depending on the device, and I have a
feeling Mark is doing the same thing.
Second of all, with respect to the spinal cord ischemia com-
ments, we too have had some patients where we have gone across
subclavian down to celiac and not had episodes or events. Early on
in our experience, we are up to close to 100 now, we had no
episodes of ischemia or paraplegia. I think the numbers just caught
up with us, and we are probably at about 5%, but that’s significantly
less than we would expect in a similar cohort of open patients.
Again, infrarenal AAA repair previously. Also, for some reason,
some of the elderly female patients with a lot of extensive arch
disease and atheroma also seem to have increased problems.
I would also echo your comments about the use of the
different types of extender cuffs. We too have run into acute
traumatic situations where you don’t have a device available. We
have actually had experience with Gore, Cook, AneuRx cuffs, and
even Zenith bodies without the legs, all of which obviously are
off-label uses. I think it will be a great help to have an FDA-
approved device (ie, the Gore device) available in the near future.
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critically important too, because I agree. I think particularly when
you have multiple catheter exchanges, multiple wire exchanges,
and/or lots of balloon manipulation and/or you are coming
around a very diseased question mark aorta and trying to go into
that transverse part of the arch, we clearly are seeing those patients
who have either subtle or perhaps not so subtle neurologic events
related to that manipulation in the arch, so again I’d like to echo
those comments as well.
And then, the final important point you made. Most of the
complications in our early experience are judgment related and
device related with respect to the iliac access. Knowing when to
stop and when to cut down and put a conduit on, I think is
critically important for anybody starting off in these programs.
Dr. Farber. Let me handle some of those real quick. Chris, in
terms of the elective simple things you, are right, but the other
group, Mel and Chris, are those emergent cases that you don’t
want to go back and reoperate for a bleeding aortobronchial fistula,
which we have treated.
In terms of the percent overlap, in terms of our components,
we had five patients that needed component or secondary proce-
dures for component insertions, two of those for overlap issues,
and exactly right those are early on. Nowwe overlap about 50%. As
devices and device components become longer, we will do that,
and that’s why that one patient didn’t get a device inserted for histype 3 endoleak at the initial procedure, because we didn’t think it
was long enough and we didn’t want to complicate things. We
figured we could just come back.
In terms of the patients with iliac access, I agree it is a
problem. You really need to get pelvic CT scans to look at that
very critically.
And the spinal cord ischemia is something that we are all going
to have to continue to work with, but it is a lot less than anyone
ever anticipated given the extensive nature of what we are doing.
Dr Frank Arko (Dallas, Tex). A quick question for your
Mark. Excellent talk. When I was at Stanford I used a lot of TE
echo so I could see whether or not there was a lot of atheromatous
or mobile atheroma up in that arch before I was manipulating any
balloons up there. When you go up and you are doing cases up in
the arch, do you use much TE in your cases?
Dr Farber. We do use TE and it is also very helpful for
dissections. I use it more for dissections than I do for simple
aneurysmal disease, but it is very critical to look at that. You are
right, it is all about your technique and deployment, because some
of these systems are not like the infrarenal. It is a push-pull, so you
do have some movement. The newer deployment systems that are
coming with the Excelerant delivery system prevents that, and I
think that we will see our stroke risks start to trickle down as the
newer development and devices and second-generation deploy-
ment systems come out.
